Is Clearance of ctDNA an Acceptable Surrogate End Point?

July 22, 2024

By Stacey A. Cohen, MD
Daniel H. Ahn, DO

Opinion

Video

Medical oncologists discuss whether ctDNA clearance can serve as an acceptable surrogate end point in the treatment of patients with colorectal cancer.

EP: 1.The Role of ctDNA as a Biomarker in Colorectal Cancer

EP: 2.Key Findings from the INTERCEPT Study

EP: 3.Frequency of ctDNA Testing and Future Directions in Detecting MRD

EP: 4.Comprehensive Insights on GALAXY Study in CIRCULATE-Japan

Now Viewing

EP: 5.Is Clearance of ctDNA an Acceptable Surrogate End Point?

EP: 6.Recent Data from BESPOKE-CRC

EP: 7.DYNAMIC Clinical Trial: ctDNA Guiding Adjuvant Therapy in Stage II Colorectal Cancer

EP: 8.COBRA: Rates of ctDNA Clearance in Assay-Directed Therapy

EP: 9.Optimizing Clinical Research and Patient Perceptions of ctDNA Testing

EP: 10.Key Takeaways on the Clinical Utility of ctDNA in Colorectal Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!